SYRE vs TGTX: stock comparison and AI forecast
Spyre Therapeutics, Inc. (SYRE) and Tg Therapeutics, Inc. (TGTX) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
SYRE Spyre Therapeutics, Inc.
- Price
- $96.59 +32.1% · 6M
- Market Cap
- $8.52B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
TGTX Tg Therapeutics, Inc.
- Price
- $57.98 +34.8% · 6M
- Market Cap
- $9.20B
- P/E Ratio
- 21.9x
- Size
- mid-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- SYRE and TGTX have similar market capitalizations ($8.52B and $9.20B).
- Over the last six months TGTX returned +34.8% and SYRE +32.1%.
- TGTX carries 1.71 times debt per unit of equity, against 0.05 times for SYRE.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | SYRE | TGTX |
|---|---|---|
| Market Cap | $8.52B | $9.20B |
| P/E Ratio | – | 21.88x |
| P/B Ratio | 8.10x | 15.23x |
| EPS | $-2.19 | $2.65 |
| Book Value/Share | $11.93 | $3.81 |
| Revenue/Share | – | $5.04 |
| FCF/Share | – | $0.11 |
Profitability & Margins
| Metric | SYRE | TGTX |
|---|---|---|
| ROE | -25.1% | 73.1% |
| ROA | -24.0% | 26.9% |
| ROIC | -23.6% | 9.9% |
| Gross Margin | – | 82.4% |
| Operating Margin | – | 17.1% |
| Net Margin | – | 55.2% |
| EBT Margin | – | 12.7% |
| Tax Rate | 0.0% | -334.5% |
Financial Health
| Metric | SYRE | TGTX |
|---|---|---|
| Current Ratio | 27.40x | 4.27x |
| Quick Ratio | – | 3.72x |
| D/E Ratio | 0.05x | 1.71x |
| Financial Leverage | 1.05x | 2.71x |
| Interest Coverage | – | 1.2x |
| Working Capital | $1.06B | $877M |
Cash Flow
| Metric | SYRE | TGTX |
|---|---|---|
| Operating Cash Flow | -$249M | $18M |
| Free Cash Flow | – | $17M |
| Capital Spending | – | -$490K |
| FCF/Sales | – | 2.2% |
| CapEx/Sales | – | 0.1% |
Operational Efficiency
| Metric | SYRE | TGTX |
|---|---|---|
| Asset Turnover | – | 0.49x |
| Receivables Turnover | – | 2.0x |
| Inventory Turnover | – | 0.9x |
| Days Sales Outstanding | – | 183 days |
| Days Inventory | – | 383 days |
Income Statement
| Metric | SYRE | TGTX |
|---|---|---|
| Total Revenue | – | $800M |
| Operating Income | -$250M | $136M |
| Net Income | -$264M | $441M |
| R&D Expense | $260M | $226M |
| SG&A Expense | – | $296M |
| Cost of Goods Sold | – | $141M |
Dividend & Shareholder Information
| Metric | SYRE | TGTX |
|---|---|---|
| Shares Outstanding | 88M | 159M |
| Net Income Growth | – | 630.2% |
| EPS Growth | – | 846.4% |
SYRE vs TGTX: stock comparison and AI forecast
Which is bigger, SYRE or TGTX?
SYRE and TGTX have similar market capitalizations ($8.52B and $9.20B).
Which stock performed better over the last six months, SYRE or TGTX?
Over the last six months TGTX returned +34.8% and SYRE +32.1%.
Which one does Intratio's AI model rank higher, SYRE or TGTX?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.